Bioequivalence Study of Two Formulations of Mifepristone Tablets in Healthy Chinese Subjects Under Fasting Conditions
- 5 May 2023
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 12 (9) , 874-880
Abstract
A single‐dose, open‐label, randomized, two‐period crossover‐design study was conducted to evaluate the bioequivalence of the reference and test formulations of mifepristone tablets. Each subject was randomized at the beginning to receive a 25‐mg tablet of the test or the reference mifepristone under fasting conditions during the first period, then received the alternate formulation during the second period following a 2‐week washout period. A validated high performance liquid chromatography‐tandem mass spectrometry (HPLC‐MS/MS) method was used to determine the plasma concentrations of mifepristone and its two metabolites (RU42633 and RU42698). Fifty‐two healthy subjects were enrolled in this trial, 50 of whom completed the study. The 90% confidence intervals for the log‐transformed Cmax, AUC0‐t, and AUC0‐∞ fell within the accepted 80%–125% range. Throughout the study period, a total of 58 treatment‐emergent adverse events were reported. No serious adverse event was observed. In conclusion, the test and reference mifepristone were bioequivalent and well tolerated under fasting conditions.Keywords
This publication has 26 references indexed in Scilit:
- Metabolic Activation of Mifepristone [RU486; 17β-Hydroxy-11β-(4-dimethylaminophenyl)-17α-(1-propynyl)-estra-4,9-dien-3-one] by Mammalian Cytochromes P450 and the Mechanism-Based Inactivation of Human CYP2B6The Journal of Pharmacology and Experimental Therapeutics, 2009
- Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortionContraception, 2006
- Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of MeningiomaCancer Investigation, 2006
- Twelve-month safety and efficacy of low-dose mifepristone for uterine myomasJournal of Minimally Invasive Gynecology, 2005
- Phase II Study of Mifepristone (RU486) in Refractory Ovarian CancerGynecologic Oncology, 2000
- Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomesBiochemical Pharmacology, 1996
- RU486: The French experienceHuman Reproduction, 1994
- A randomized clinical trial of mifepristone (RU486) for induction of delayed menses: Efficacy and acceptabilityContraception, 1992
- Successful mifepristone treatment of recurrent, inoperable meningiomaThe Lancet, 1990
- Plasma concentrations and receptor binding of RU 486 and its metabolites in humansThe Journal of Steroid Biochemistry and Molecular Biology, 1987